Skeletal muscle mitochondrial capacity in people with multiple sclerosis

Mary Ann Harp, Kevin K McCully, Marina Moldavskiy, Deborah Backus, Mary Ann Harp, Kevin K McCully, Marina Moldavskiy, Deborah Backus

Abstract

Background: People with multiple sclerosis (MS) have functional disability and may have reduced muscle mitochondrial capacity.

Objective: The objective of this paper is to measure muscle mitochondrial capacity of leg muscles using near-infrared spectroscopy (NIRS) and compare to functional status.

Materials and methods: People with MS (n = 16) and a control (CON) group (n = 9) were evaluated for 25-ft walk time. Mitochondrial capacity of both gastrocnemius muscles were measured with NIRS as the rate of recovery of oxygen consumption in after exercise.

Results: Mitochondrial capacity was lower in the MS group compared to the CON group (rate constants: 1.13 ± 0.29 vs. 1.68 ± 0.37 min-1, p < 0.05). There was a tendency for people with MS who used assistive devices to have lower mitochondrial capacity in the weaker leg (p = 0.07).

Conclusion: NIRS measurements of mitochondrial capacity suggest a 40% deficit in people with MS compared to CONs and this may contribute to walking disability.

Keywords: 25-foot walk; Near-infrared spectroscopy.

Figures

Figure 1.
Figure 1.
Individual values for mitochondrial capacity of dominant (DOM) and non-dominant (NON-DOM) legs in the control participants (CON) and the strong and weak legs in people with multiple sclerosis (MS). AVG: average. Mean values are solid squares with SD.
Figure 2.
Figure 2.
(a) Results of timed 25-foot walk test. The multiple sclerosis (MS) group is ordered from fastest to slowest walking speeds. The gray shaded box represents the 95% confidence interval of completion times observed in the control group. (b) Mitochondrial capacity for the MS group ordered from the lowest to the highest mitochondrial capacity. Circles represent those participants with MS who used an assistive device and squares represent those who did not. Shaded symbols represent relapsing–remitting MS, solid symbols secondary progressive MS, and open symbols type of MS unknown.
Figure 3.
Figure 3.
Comparisons of muscle mitochondrial capacity between groups of participants. Multiple sclerosis (MS) and control groups (CON) are from this study. Previously published data from highly trained cyclists, people with amyloid lateral sclerosis (ALS) and motor complete spinal cord injury (SCI). All the presented groups were significantly different from their respective control groups (p < 0.05).

References

    1. White LJ, Dressendorfer RH. Exercise and multiple sclerosis. Sports Med 2004; 34: 1077–1100.
    1. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002; 8: 359–365.
    1. Kumleh HH, Riazi GH, Houshmand M, et al. Complex I deficiency in Persian multiple sclerosis patients. J Neurol Sci 2006; 243: 65–69.
    1. Kent-Braun JA, Ng AV, Castro M, et al. Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. J Appl Physiol (1985) 1997; 83: 1998–2004.
    1. Kent-Braun JA, Sharma KR, Miller RG, et al. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle Nerve 1994; 17: 835–841.
    1. Chung LH, Remelius JG, Van Emmerik RE, et al. Leg power asymmetry and postural control in women with multiple sclerosis. Med Sci Sport Exer 2008; 40: 1717–1724.
    1. Larson RD, McCully KK, Larson DJ, et al. Bilateral differences in lower-limb performance in individuals with multiple sclerosis. J Rehabil Res Dev 2013; 50: 215–221.
    1. Hansen D, Feys P, Wens I, et al. Is walking capacity in subjects with multiple sclerosis primarily related to muscle oxidative capacity or maximal muscle strength? A pilot study. Mult Scler Int 2014; 2014: 759030.
    1. Hamaoka T, McCully KK, Quaresima V, et al. Near-infrared spectroscopy/imaging for monitoring muscle oxygenation and oxidative metabolism in healthy and diseased humans. J Biomed Opt 2007; 12: 062105.
    1. Ryan TE, Southern WM, Reynolds MA, et al. A cross-validation of near-infrared spectroscopy measurements of skeletal muscle oxidative capacity with phosphorus magnetic resonance spectroscopy. J Appl Physiol (1985) 2013; 115: 1757–1766.
    1. Southern WM, Ryan TE, Reynolds MA, et al. Reproducibility of near-infrared spectroscopy measurements of oxidative function and postexercise recovery kinetics in the medial gastrocnemius muscle. Appl Physiol Nutr Metab 2014; 39: 521–529.
    1. Ryan TE, Brizendine JT, McCully KK. A comparison of exercise type and intensity on the noninvasive assessment of skeletal muscle mitochondrial function using near-infrared spectroscopy. J Appl Physiol (1985) 2013; 114: 230–237.
    1. Ryan TE, Southern WM, Brizendine JT, et al. Activity-induced changes in skeletal muscle metabolism measured with optical spectroscopy. Med Sci Sports Exerc 2013; 45: 2346–2352.
    1. Erickson ML, Ryan TE, Brizendine JT, et al. Measuring skeletal muscle metabolism with near-infrared spectroscopy. Med Sci Sport Exer 2012; 44: 231.
    1. Booth M. Assessment of physical activity: An international perspective. Res Q Exerc Sport 2000; 71(2 Suppl): S114–S120.
    1. Erickson ML. Evaluation of skeletal muscle oxidative capacity in persons with spinal cord injury with near-infrared spectroscopy. Master’s Thesis, University of Georgia, USA, 2012.
    1. Ansari NN, Naghdi S, Arab TK, et al. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: Limb and muscle group effect. NeuroRehabilitation 2008; 23: 231–237.
    1. Larson RD, Larson DJ, Baumgartner TB, et al. Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis. Clin Rehabil 2013; 27: 719–723.
    1. Ryan TE, Erickson ML, Brizendine JT, et al. Noninvasive evaluation of skeletal muscle mitochondrial capacity with near-infrared spectroscopy: Correcting for blood volume changes. J Appl Physiol (1985) 2012; 113: 175–183.
    1. Erickson ML, Ryan TE, Young HJ, et al. Near-infrared assessments of skeletal muscle oxidative capacity in persons with spinal cord injury. Eur J Appl Physiol 2013; 113: 2275–2283.
    1. Ryan TE, Erickson ML, Verma A, et al. Skeletal muscle oxidative capacity in amyotrophic lateral sclerosis. Muscle Nerve 2014; 50: 767–774.
    1. Brizendine JT, Ryan TE, Larson RD, et al. Skeletal muscle metabolism in endurance athletes with near-infrared spectroscopy. Med Sci Sports Exerc 2013; 45: 869–875.
    1. Malagoni AM, Felisatti M, Lamberti N, et al. Muscle oxygen consumption by NIRS and mobility in multiple sclerosis patients. BMC Neurol 2013; 13: 52.
    1. Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurology 2014; 14: 58.
    1. Larson RD. Psychometric properties of the Modified Fatigue Impact Scale. Int J MS Care 2013; 15: 15–20.
    1. O’Connor P. Mental and Physical State and Trait Energy and Fatigue scales, Athens, GA: University of Georgia, 2016.
    1. Ferrari M, Mottola L, Quaresima V. Principles, techniques, and limitations of near infrared spectroscopy. Can J Appl Physiol 2004; 29: 463–487.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel